Business Wire

Rogers Communications Selects Gemalto to Secure Mobile NFC Payment Solutions

9.10.2012 15:00:44 CEST | Business Wire | Press release

Share
GEMALTO/ROGERS-COMM.

Mobile payments on Rogers NFC-enabled devices to be protected by Gemalto’s SIM-based software security

Rogers Communications (TSX: RCI.A and RCI.B) and Gemalto (Euronext NL0000400653 GTO) announced today that mobile payment solutions currently in pilot testing and coming to market this year on Rogers NFC-enabled devices will be secured by digital security technology from Gemalto. Rogers will deploy the UpTeq NFC , Gemalto’s EMV-ready, high-end SIM-UICC solution, to store and secure consumers credentials and card data required to make payments with NFC-enabled mobile devices.

It’s essential that consumers have peace of mind when it comes to storing payment cards on their mobile device and using it to make credit and debit transactions on the go,” said David Robinson, Vice-President, Emerging Business, Rogers Communications. “Working with Gemalto allows us to protect the consumer’s information by leveraging the SIM card, assuring a secure and seamless experience for mobile payments.

Rogers is deploying the UpTeq NFC to secure payment credentials stored on the high-end SIM for new mobile payment services that are expected to launch in Canada later this year, and will leverage the card’s onboarding flexibility for the future addition of tap-and-go services including coupon redemption, loyalty programs, transit, and other digital identification. The UpTeq NFC secure device, which has an identical form factor as a conventional SIM, is part of Gemalto’s UpTeq LTE offer, and fully compliant over LTE networks. The payment services that Rogers expects to deliver to banks will fully comply with EMV, the global standard for secure credit and debit card transactions based on microprocessor chip technology that protects information needed for secure payments. The software application and the UpTeq NFC device have both successfully achieved the compliance assessment and security testing certification in accordance with MasterCard and Visa’s highest security requirements.

Gemalto has the global experience and capabilities, deploying and having deployed more than 50 mobile NFC projects worldwide. The company has a long history of being entrusted by thousands of banks and mobile operators around the world to provide best-in-class solutions for digital security” said Sébastien Cano, senior vice president of Telecommunications at Gemalto North America. “We have worked closely with Rogers to develop a highly scalable and secure solution for mobile payment that leverages the SIM as our industry’s most cost-effective security ingredient - Rogers is leading the way for the future of mobile payments.

Canada has been on the forefront of global payments technology and as a result, tens of thousands of Canadian retailers are already equipped with contactless point-of-sale (POS) terminals that today accept contactless banking cards and are hence capable of supporting the mobile payment solutions on NFC-enabled devices - among them fast food outlets, gasoline stations, grocery and convenience stores and coffee shops.

No. No. No.

Editor's note on contactless and NFC

NFC stands for Near Field Communication, a radio-communication protocol designed for consumer devices to communicate directly with one another at very short range.
Extending the ability of the contactless card technology, NFC is backward compatible with the existing contactless standards and infrastructure, which supports payment brand applications such as MasterCard PayPass, Visa PayWave, DiscoverZip or American Express ExpressPay. As a result, NFC handsets in card emulation mode can be used to perform secure contactless payment transactions. With the emergence of mobile NFC services, payment terminals are enhanced with additional applications such as ticketing, mobile coupon redemption, information access from smart posters or access control systems with a simple touch.

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the world leader in digital security with 2011 annual revenues of €2 billion and more than 10,000 employees operating out of 74 offices and 14 Research & Development centers, located in 43 countries.

We are at the heart of the rapidly evolving digital society. Billions of people worldwide increasingly want the freedom to communicate, travel, shop, bank, entertain and work – anytime, everywhere – in ways that are enjoyable and safe. Gemalto delivers on their expanding needs for personal mobile services, payment security, authenticated cloud access, identity and privacy protection, eHealthcare and eGovernment efficiency, convenient ticketing and dependable machine-to-machine (M2M) applications.

Gemalto develops secure embedded software and secure products which we design and personalize. Our platforms and services manage these secure products, the confidential data they contain and the trusted end-user services they enable. Our innovations offer more ways for our clients to enhance the convenience and security of people’s digital lives.

Gemalto thrives with the growing number of people using its solutions to interact with the digital and wireless world.

For more information visit www.gemalto.com , www.justaskgemalto.com , blog.gemalto.com , or follow @gemalto on Twitter.

About Rogers Communications
Rogers Communications is a diversified Canadian communications and media company. We are Canada's largest provider of wireless voice and data communications services and one of Canada's leading providers of cable television, high speed internet and telephony services. Through Rogers Media we are engaged in radio and television broadcasting, televised shopping, magazines and trade publications, sports entertainment, and digital media. We are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For further information about the Rogers group of companies, please visit rogers.com .

Contact:

Gemalto Media Contacts:
Nicole Smith
North America
+1 512 758 8921
nicole.smith@gemalto.com
or
Ernesto Haikewitsch
Latin America
+55 11 51 05 92 20
ernesto.haikewitsch@gemalto.com
or
Kristel Teyras
Europe, Middle East & Africa
+33 1 55 01 57 89
kristel.teyras@gemalto.com
or
Yvonne Lim
Asia Pacific
+65 6317 3730
yvonne.lim@gemalto.com
or
Rogers Communications :
Allison Fitton
416-935-8860,
allison.fitton@rci.rogers.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye